Your browser doesn't support javascript.
loading
Impact of Systemic Delays for Patient Access to Oncology Drugs on Clinical, Economic, and Quality of Life Outcomes in Canada: A Call to Action.
Sehdev, Sandeep; Gotfrit, Joanna; Elias, Martine; Stein, Barry D.
Afiliación
  • Sehdev S; The Ottawa Hospital Cancer Centre, Ottawa, ON K1H 8L6, Canada.
  • Gotfrit J; The Ottawa Hospital Cancer Centre, Ottawa, ON K1H 8L6, Canada.
  • Elias M; Myeloma Canada, Dorval, QC H9P 2V4, Canada.
  • Stein BD; Colorectal Cancer Canada, Montreal, QC H3Z 2P9, Canada.
Curr Oncol ; 31(3): 1460-1469, 2024 03 11.
Article en En | MEDLINE | ID: mdl-38534943
ABSTRACT
Canada has one of the most complex and rigorous drug approval and public reimbursement processes and is, unfortunately, one of the countries with the longest delays in drug access. To assess the overall impact of systemic delays in access to cancer therapy, a targeted literature review (TLR) was performed to identify studies associated with the clinical, economic, and quality of life impacts of delayed access to oncology drugs. Using MEDLINE/PubMed databases and snowballing, four unique records met the eligibility criteria. Results revealed that clinical outcomes were the most impacted by systemic delays in access to oncology drugs (e.g., life years lost, overall survival, and progression-free survival). The four articles retrieved by the TLR specifically illustrated that a substantial number of life years could potentially be saved by increasing systemic efficiency regarding the development, approval, and reimbursement processes of new drugs for advanced malignancies. It is imperative that initiatives are put in place to improve the performance and speed of Canadian drug regulatory and health technology assessment (HTA) processes, especially for new cancer therapeutics. The proposed solutions in this paper include better coordination between HTA and Canadian payers to harmonize coverage decisions, international collaborations, information sharing, and national standards for timeliness in oncology drug access.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Calidad de Vida / Neoplasias Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: Curr Oncol Año: 2024 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Suiza

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Calidad de Vida / Neoplasias Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: Curr Oncol Año: 2024 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Suiza